JP2024539872A5 - - Google Patents
Info
- Publication number
- JP2024539872A5 JP2024539872A5 JP2024522407A JP2024522407A JP2024539872A5 JP 2024539872 A5 JP2024539872 A5 JP 2024539872A5 JP 2024522407 A JP2024522407 A JP 2024522407A JP 2024522407 A JP2024522407 A JP 2024522407A JP 2024539872 A5 JP2024539872 A5 JP 2024539872A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263224P | 2021-10-28 | 2021-10-28 | |
| US63/263,224 | 2021-10-28 | ||
| PCT/US2022/048037 WO2023076485A1 (en) | 2021-10-28 | 2022-10-27 | Combination therapies comprising wee1 inhibitors and dna damage response (ddr) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539872A JP2024539872A (ja) | 2024-10-31 |
| JP2024539872A5 true JP2024539872A5 (enExample) | 2025-11-05 |
Family
ID=86158503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522407A Pending JP2024539872A (ja) | 2021-10-28 | 2022-10-27 | Ｗｅｅ１阻害剤及びｄｎａ損傷応答（ｄｄｒ）阻害剤を含む併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240299395A1 (enExample) |
| EP (1) | EP4422624A4 (enExample) |
| JP (1) | JP2024539872A (enExample) |
| CN (1) | CN118234493A (enExample) |
| TW (1) | TW202333729A (enExample) |
| WO (1) | WO2023076485A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| WO2025186213A1 (en) * | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017127088A (ru) * | 2010-11-16 | 2019-02-04 | Эррэй Биофарма Инк. | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 |
| WO2013039854A1 (en) * | 2011-09-15 | 2013-03-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
-
2022
- 2022-10-27 EP EP22888179.3A patent/EP4422624A4/en active Pending
- 2022-10-27 JP JP2024522407A patent/JP2024539872A/ja active Pending
- 2022-10-27 WO PCT/US2022/048037 patent/WO2023076485A1/en not_active Ceased
- 2022-10-27 CN CN202280066997.3A patent/CN118234493A/zh active Pending
- 2022-10-27 TW TW111140882A patent/TW202333729A/zh unknown
-
2024
- 2024-04-26 US US18/648,164 patent/US20240299395A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024539872A5 (enExample) | ||
| CN104066731B (zh) | 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类 | |
| US20210221793A1 (en) | Pyrazole derivatives as sgc stimulators | |
| RU2430099C2 (ru) | Тозилатная соль терапевтического соединения и ее фармацевтические композиции | |
| JP5878546B2 (ja) | ｓＧＣ刺激剤 | |
| US7601868B2 (en) | Amine derivative | |
| JP2024520630A5 (enExample) | ||
| JP2004520292A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| JP2013527202A5 (enExample) | ||
| JP2005533860A5 (enExample) | ||
| JP2021513981A5 (enExample) | ||
| JP2013531028A5 (enExample) | ||
| JP2021533152A5 (enExample) | ||
| JP2019536812A5 (enExample) | ||
| CZ20014015A3 (cs) | Pouľití ligandů D3 receptorů dopaminu pro výrobu léčiv pro léčení poruch funkce ledvin | |
| JP2009511450A5 (enExample) | ||
| JP2021530525A (ja) | ループス腎炎を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド | |
| JP2024041835A (ja) | 置換テトラヒドロシクロペンタ［ｃ］ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法 | |
| JP5941258B2 (ja) | 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール | |
| JP2006512321A5 (enExample) | ||
| CN117482102A (zh) | 使用5′-腺苷二磷酸核糖(adpr)的方法 | |
| WO2020245365A1 (en) | Methods of treating cancer using prmt5 inhibitors | |
| CN103379917A (zh) | 药物组合物 | |
| JP2011519964A (ja) | 聴覚障害の処置用のｓＧＣ刺激剤、ｓＧＣ活性化剤およびそれらの組合せ |